Breaking News
Sort by:
Top Post
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]
Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs
Immunovia, the diagnostics company that has launched the world’s first blood test dedicated to the […]
The PanDIA-1 Study, for Early Detection of Pancreatic Cancer in Newly Onset Type 2 Diabetics, Moves Into Next Phase
Immunovia today announced the PanDIA-1 study for the early detection of pancreatic cancer in newly […]
Immunovia Appoints Jeff Borcherding, Previously Chief Marketing Officer at Myriad Genetics, to Lead Immunovia's US Business
Immunovia (Nasdaq Stockholm: IMMNOV) has appointed Jeff Borcherding as CEO of its US subsidiary Immunovia, Inc. He […]
Immunovia Further Strengthens IP Portfolio for its IMMray ™ PanCan-d Signature
Immunovia AB (publ) announced today that the United States Patent and Trademark Office (USPTO) has […]
- Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Read more
- Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) Read more
- BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Read more
- Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution Read more
- GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Read more